FR2868424B1 - Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique - Google Patents

Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique

Info

Publication number
FR2868424B1
FR2868424B1 FR0403378A FR0403378A FR2868424B1 FR 2868424 B1 FR2868424 B1 FR 2868424B1 FR 0403378 A FR0403378 A FR 0403378A FR 0403378 A FR0403378 A FR 0403378A FR 2868424 B1 FR2868424 B1 FR 2868424B1
Authority
FR
France
Prior art keywords
antibodies
diagnostic
therapeutic applications
glycopeptides derived
pancreatic structures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0403378A
Other languages
English (en)
Other versions
FR2868424A1 (fr
Inventor
Dominique Lombardo
Eric Mas
Marie Odile Sadoulet
Dubois Laurence Panicot
Jean Paul Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aix Marseille Universite
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de la Mediterranee
Universite de la Mediterranee Aix Marseille II
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0403378A priority Critical patent/FR2868424B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite de la Mediterranee, Universite de la Mediterranee Aix Marseille II filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to JP2007505595A priority patent/JP5066445B2/ja
Priority to US10/593,859 priority patent/US7557193B2/en
Priority to EP05746926.4A priority patent/EP1730270B1/fr
Priority to DK05746926.4T priority patent/DK1730270T3/en
Priority to CA2558754A priority patent/CA2558754C/fr
Priority to AU2005229451A priority patent/AU2005229451B2/en
Priority to PCT/FR2005/000771 priority patent/WO2005095594A1/fr
Publication of FR2868424A1 publication Critical patent/FR2868424A1/fr
Application granted granted Critical
Publication of FR2868424B1 publication Critical patent/FR2868424B1/fr
Priority to US12/488,793 priority patent/US8367062B2/en
Priority to JP2011243732A priority patent/JP5977936B2/ja
Priority to JP2014205188A priority patent/JP2015063524A/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
FR0403378A 2004-03-31 2004-03-31 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique Expired - Fee Related FR2868424B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0403378A FR2868424B1 (fr) 2004-03-31 2004-03-31 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique
PCT/FR2005/000771 WO2005095594A1 (fr) 2004-03-31 2005-03-30 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique
EP05746926.4A EP1730270B1 (fr) 2004-03-31 2005-03-30 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique
DK05746926.4T DK1730270T3 (en) 2004-03-31 2005-03-30 Glycopeptides DERIVED FROM pancreatic STRUCTURES, ANTIBODIES AND APPLICATIONS THEREOF IN DIAGNOSIS AND therapeutics
CA2558754A CA2558754C (fr) 2004-03-31 2005-03-30 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique
AU2005229451A AU2005229451B2 (en) 2004-03-31 2005-03-30 Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
JP2007505595A JP5066445B2 (ja) 2004-03-31 2005-03-30 膵構造から誘導される糖ペプチド、抗体ならびに診断および治療におけるそれらの応用
US10/593,859 US7557193B2 (en) 2004-03-31 2005-03-30 Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
US12/488,793 US8367062B2 (en) 2004-03-31 2009-06-22 Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics
JP2011243732A JP5977936B2 (ja) 2004-03-31 2011-11-07 膵構造から誘導される糖ペプチド、抗体ならびに診断および治療におけるそれらの応用
JP2014205188A JP2015063524A (ja) 2004-03-31 2014-10-03 膵構造から誘導される糖ペプチド、抗体ならびに診断および治療におけるそれらの応用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0403378A FR2868424B1 (fr) 2004-03-31 2004-03-31 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique

Publications (2)

Publication Number Publication Date
FR2868424A1 FR2868424A1 (fr) 2005-10-07
FR2868424B1 true FR2868424B1 (fr) 2008-04-11

Family

ID=34946085

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0403378A Expired - Fee Related FR2868424B1 (fr) 2004-03-31 2004-03-31 Glycopeptides derives de structures pancreatiques, anticorps et leurs applications en diagnostic et therapeutique

Country Status (1)

Country Link
FR (1) FR2868424B1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4130A (is) * 1993-03-01 1994-09-02 Ab Astra Ný fjölpeptíð

Also Published As

Publication number Publication date
FR2868424A1 (fr) 2005-10-07

Similar Documents

Publication Publication Date Title
FR2888850B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
MA30684B1 (fr) Anticorps anti-mn et leurs procedes d'utilisation.
FR15C0048I2 (fr) Anticorps antagonistes de il-17
FR2910473B1 (fr) Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
FR2882054B1 (fr) Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique
MA28489B1 (fr) Preparations pharmaceutiques
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
CY2200165T2 (el) Εξωτερικα εφαρμοζομενο συστημα διεπαφης ασθενους και μεθοδος
FR2888847B1 (fr) Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
MA28575B1 (fr) Derives de la 1-amino-phthalazine, leur preparation , et leur application en therapeutique
PT102854B (pt) Sistema de aplicacao de medicamento bioadesivo
MA28734B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2904316B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
MA28343A1 (fr) Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR18C1032I2 (fr) Anticorps anti-fgf23 et composition pharmaceutique le comprenant
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
MA29017B1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
FR2866888B1 (fr) Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique
FR2891825B1 (fr) Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique
FR2888848B1 (fr) Derives de n-(arylalkyl)-1h-pyrrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
FR2873690B1 (fr) Derives d'oxopiperidine, leur preparation et leur application en therapeutique
FR2892416B1 (fr) Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
FR2887548B1 (fr) Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
TQ Partial transmission of property

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20121115

Owner name: UNIVERSITE D'AIX MARSEILLE, FR

Effective date: 20121115

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

ST Notification of lapse

Effective date: 20191106